| Broadly neutralizing antibodies against influenza neuraminidase |
2023-6-07 |
2023-8-18 |
|
| Antibodies against SARS-CoV-2 and methods of using the same |
2023-5-22 |
2023-6-15 |
|
| Hiv vaccines comprising one or more population episensus antigens |
2023-1-12 |
2023-4-26 |
|
| Treatment of respiratory virus infection by modulation of the n-glycosylation … |
2022-12-16 |
2023-7-06 |
|
| Heterocycle derivatives for the treatment of disease |
2022-12-15 |
2023-6-22 |
|
| Antibodies against sars-cov-2 |
2022-12-06 |
2023-3-07 |
|
| Enpp1 modulators and uses thereof |
2022-11-16 |
2023-6-15 |
|
| Enpp1 modulators and uses thereof |
2022-11-14 |
2023-5-19 |
|
| Virological and molecular surrogates of response to sars-cov-2 neutralizing … |
2022-11-14 |
2023-5-19 |
|
| Small molecule inducers of autophagy |
2022-11-03 |
2023-5-11 |
|
| Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
2022-9-07 |
2023-3-16 |
|
| High concentration antibody therapies for sars-cov-2 infection |
2022-8-31 |
2023-3-09 |
|
| Antibody therapies for sars-cov-2 infection in pediatric subjects |
2022-8-31 |
2023-3-09 |
|
| Methods for producing cmv vectors |
2022-8-30 |
2023-5-16 |
|
| Tuberculosis vaccines |
2022-8-30 |
2023-3-09 |
|
| Recombinant hcmv vectors and uses thereof |
2022-8-30 |
2023-3-16 |
|
| Engineered compositions |
2022-8-26 |
2023-4-16 |
|
| Predicting mutational drivers of future pathogen spread |
2022-6-17 |
2022-12-29 |
|
| Engineered polypeptides |
2022-5-23 |
2023-1-12 |
|
| COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
2022-5-12 |
2022-11-17 |
|
| COMBINATION OF A TLR8 MODULATION COMPOUND AND ANTI-HBV THERAPEUTICS WITH siRNA |
2022-5-12 |
2023-8-23 |
|
| Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
2022-4-27 |
2022-11-03 |
|
| Antibodies that bind to multiple sarbecoviruses |
2022-3-22 |
2022-9-29 |
|
| Hepatitis b virus vaccines |
2022-2-27 |
2022-4-01 |
|
| Antibody compositions and methods for treating hepatitis b virus infection |
2022-2-27 |
2022-4-01 |
|
| Compositions and methods for treatment of influenza a infection |
2022-2-20 |
2022-4-01 |
|
| Compositions and methods for treating hepatitis b virus infection |
2022-1-25 |
2023-5-25 |
|
| Antibody combination therapies for sars-cov-2 infection |
2022-1-24 |
2022-7-28 |
|
| Antibodies and methods for treatment of influenza a infection |
2021-12-07 |
2022-10-01 |
|
| Antibodies that bind to multiple betacoronaviruses |
2021-11-23 |
2022-6-02 |
|
| ANTIBODIES THAT BIND MULTIPLE BETACORONAVIRUS |
2021-11-23 |
2023-2-15 |
|
| Anti-influenza antibodies and combinations thereof |
2021-11-19 |
2022-5-27 |
|
| ANTIBODIES AGAINST INFLUENZA A VIRUSES |
2021-11-19 |
2023-2-15 |
|
| Antibodies against influenza a viruses |
2021-11-19 |
2022-5-27 |
|
| BROADLY NEUTRALIZING ANTIBODIES AGAINST INFLUENZA NEURAMINIDASE |
2021-11-19 |
2023-2-15 |
|
| ANTI-INFLUENZA ANTIBODIES AND COMBINATIONS THEREOF |
2021-11-19 |
2023-2-15 |
|
| Compositions and methods for treating hepatitis b virus (hbv) infection |
2021-11-11 |
2022-1-01 |
|
| Coronavirus irna compositions and methods of use thereof |
2021-11-10 |
2022-4-28 |
|
| Antibodies against sars-cov-2 |
2021-9-28 |
2022-3-31 |
|
| Predictive universal signatures for multiple disease indications |
2021-8-06 |
2022-2-10 |
|
| Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
2021-8-01 |
2021-9-30 |
|
| Engineered hepatitis b virus neutralizing antibodies and uses thereof |
2021-6-23 |
2023-5-03 |
|
| Engineered hepatitis B virus neutralizing antibodies and uses thereof. |
2021-6-23 |
2023-8-24 |
|
| Combination hbv therapy |
2021-6-15 |
2021-8-31 |
|
| Antibody therapies for sars-cov-2 infection |
2021-6-11 |
2021-12-16 |
|
| ANTIBODY THERAPIES FOR SARS-CoV-2 INFECTION |
2021-6-11 |
2022-9-21 |
|
| Structure-guided immunotherapy against sars-cov-2 |
2021-6-03 |
2021-12-09 |
|
| Antibodies against sars-cov-2 |
2021-6-01 |
2022-3-16 |
|
| Antibodies against sars-cov-2 and methods of using the same |
2021-6-01 |
2022-2-01 |
|
| ANTIBODIES AGAINST SARS-CoV-2 |
2021-6-01 |
2023-4-19 |
|
| ANTIBODIES AGAINST SARS-CoV-2 AND METHODS OF USE THEM |
2021-6-01 |
2023-1-18 |
|
| Antibodies against SARS-COV-2 |
2021-5-07 |
2023-9-12 |
|
| Antibodies against sars-cov-2 and methods of using the same |
2021-4-14 |
2021-10-21 |
|
| Immunotherapy targeting a conserved region in sars coronaviruses |
2021-4-02 |
2021-10-07 |
|
| RNAi COMPOSITIONS AGAINST CORONAVIRUS AND METHODS OF USE THEREOF |
2021-3-25 |
2022-6-29 |
|
| Engineered microorganisms and methods of making and using same |
2021-3-21 |
2021-5-31 |
|
| ANTIBODIES AGAINST SARS-COV-2 AND METHODS TO USE THEM |
2021-2-25 |
2022-6-08 |
|
| Antibodies against SARS-COV-2 and methods of use thereof |
2021-2-02 |
2023-2-03 |
|
| Compositions and methods for treating hepatitis B virus (HBV) infection. |
2020-5-12 |
2022-10-27 |
|
| BINDING OF ANTIBODIES TO PLASMODIUM CIRCUNSPOROZOITE PROTEIN AND USES THEREOF |
2020-4-30 |
2021-10-26 |
|
| Antibodies binding to plasmodium circumsporozoite protein and uses thereof. |
2020-4-30 |
2023-6-27 |
|
| Ligação de anticorpos à proteína circunsporozoíta de plasmódio e usos da mesma |
2020-4-30 |
2021-10-26 |
|